GEA
BTAI icon

Glen Eagle Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Glen Eagle Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21
Closed -$10K – 955
2021
Q3 		$10K Sell
21
-4
-16% -$1.76K ﹤0.01% 697
2021
Q2 		$11.8K Buy
25
+8
+47% +$4.36K ﹤0.01% 663
2021
Q1 		$11.7K Buy
17
+2
+13% +$1.61K ﹤0.01% 637
2020
Q4 		$11.1K Buy
15
+13
+650% +$10.1K ﹤0.01% 616
2020
Q3 		$1.08K Hold
2
– – ﹤0.01% 839
2020
Q2 		$1.32K Buy
+2
New +$1.3K ﹤0.01% 791

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Glen Eagle Advisors's BTAI Position: Q4 2021 in Review

Glen Eagle Advisors sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 21 shares — an estimated $10K sold.

Glen Eagle Advisors first reported a position in BTAI in Q2 2020 and held it in 6 quarters. The position peaked at $11.8K in Q2 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Glen Eagle Advisors reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 21 BioXcel Therapeutics shares in Q4 2021, an estimated $10K.
  • Glen Eagle Advisors first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 6 quarters.
  • Glen Eagle Advisors's BioXcel Therapeutics position peaked at $11.8K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.